# FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma

> **NCT06332092** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fulgent Pharma LLC.** · enrollment: 46 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** FID007

## Key facts

- **NCT ID:** NCT06332092
- **Lead sponsor:** Fulgent Pharma LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-10
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06332092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06332092, "FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06332092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*